In this podcast, our Chief Operations Officer & founder, John Waller, was invited onto the hugely popular Digital Pathology Today podcast.
John and the podcast host, Dr. Joseph Anderson, chat about OracleBio’s humble beginnings and our quantitative digital pathology journey over the past decade – from a single company laptop to a cutting-edge, scalable cloud computing infrastructure.
They covered a number of interesting topics, including:
- OracleBio’s history, mission, and field of practice
- Good Clinical Practice
- How Digital Pathology has evolved over the years and what its future holds
- Pathologist-led image analysis and the difficulties humans face with detailed quantification
- Artificial Intelligence: Machine Learning and Deep Learning
The importance of cloud computing and automation - …and a whole lot more!
Be sure to check out more episodes on the Digital Pathology Today website.
Reasons to Work With OracleBio:
Data you can trust – We have thorough quality control procedures in place throughout our workflow to ensure the data we provide is of a high-quality standard
Latest technologies – We continually invest time and money into the latest software and techniques so you don’t need to
More from OracleBio:
Quantification of Dual LAG-3 and CD3 IHC-stained T Cells in Clinical Tumor Tissue using Image Analysis
The characterisation of immune cells within the tumor microenvironment and their potential impact on cancer treatment and prognosis has been the subject of intense investigation over recent years. Non-small cell lung cancer (NSCLC) patients have impaired immune...
Quality Counts: Implementing Quality Standards as part of Image Analysis in Clinical R&D
Delivering robust and meaningful data in support of an ever-increasing demand on tissue-based biomarker evaluations is critical to improving decision making in clinical R&D. To realise these requirements, it is vitally important to implement quality standards...
Use of histology image analysis to aid selection of oncology xenograft models for drug development
The development of new oncology therapies is routinely supported through the use of various xenograft models. Identifying the most suitable models for use in pre-clinical oncology programmes is key to establishing a successful translational R&D strategy. The...
Find out more about our Software Capabilities
OracleBio's Quantitative Digital Pathology Services
Stay up to date with OracleBio
Sign up to our mailing list to stay informed about news, webinars, events and more



